RSNA 2014 

Abstract Archives of the RSNA, 2014


NMS176

Changes in Pulmonary 18F-FDG PET Uptake Reflect Treatment Response in Patients with Diffuse Parenchymal Lung Disease

Scientific Posters

Presented on December 2, 2014
Presented as part of NMS-TUB: Nuclear Medicine Tuesday Poster Discussions

Participants

Nicholas J. Screaton BMBCh, Abstract Co-Author: Nothing to Disclose
Thida Win, Abstract Co-Author: Nothing to Disclose
Joanna C. Porter PhD, FRCP, Abstract Co-Author: Advisor, Onyx Pharmaceuticals, Inc Advisor, InterMune, Inc
Lynn Millner, Abstract Co-Author: Research funded, GlaxoSmithKline plc
Francesco Fraioli MD, Presenter: Nothing to Disclose
Ashley McAllister Groves MBBS, Abstract Co-Author: Investigator, GlaxoSmithKline plc Investigator, General Electric Company Investigator, Siemens AG

PURPOSE

Noninvasive markers of disease activity in diffuse parenchymal lung disease (DPLD) are lacking, which is delaying the end points for clinical trials. We investigate the potential of 18F-FDG-PET/CT to assess disease activity and monitor treatment response in DPLD patients with mixed reticular ground glass changes on high resolution computed tomography (HRCT).

METHOD AND MATERIALS

Twenty-one patients (11-male, 10-female, mean age 68±11) with DPLD were prospectively recruited. Two patients had biopsy proven non-specific interstitial pneumonia (NSIP). The other 19-patients had mixed interstitial inflammation and fibrosis consistent with NSIP following multidisciplinary review on the basis of clinical, pulmonary function tests (PFTs) and HRCT. PFTs and thoracic 18FDG-PET/CT were performed pre and post-treatment. Pulmonary FDG uptake (SUVmax) was calculated pre and post-treatment.

RESULTS

Changes in pulmonary SUVmax correlated with pulmonary function changes post-treatment (FEV1 r=-0.60, p=0.004; FVC r=-0.65, p=0.001; TLco r=-0.65, p=0.004). In addition, pretreatment SUVmax correlated with post treatment SUVmax (r= 0.51, p=0.019).

CONCLUSION

18FDG-PET/CT has potential as a biomarker in patients with DPLD with a mixed reticular ground-glass HRCT appearance

CLINICAL RELEVANCE/APPLICATION

18FDG PET/CT has potential to monitor treatment response in patients with NSIP

Cite This Abstract

Screaton, N, Win, T, Porter, J, Millner, L, Fraioli, F, Groves, A, Changes in Pulmonary 18F-FDG PET Uptake Reflect Treatment Response in Patients with Diffuse Parenchymal Lung Disease.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14045663.html